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Purpose: To compare an intensity-modulated radiotherapy (IMRT) planning approach for prostate pelvic RTwith
a conformal RT (CRT) approach taking into account the inﬂuence of organ-at-risk (OAR) motion.
Methods andMaterials: A total of 20 male patients, each with one planning computed tomography scan and ﬁve to
eight treatment computed tomography scans, were used for simulation of IMRT and CRT for delivery of a pre-
scribed dose of 50 Gy to the prostate, seminal vesicles, and pelvic lymph nodes. Planning was done in Eclipse with-
out correcting for OAR motion. Evaluation was performed using the CRT and IMRT dose matrices and the
planning and treatment OAR outlines. The generalized equivalent uniform dose (gEUD) was calculated for 894
OAR volumes using a volume–effect parameter of 4, 12, and 8 for bowel, rectum and bladder, respectively. For
the bowel, the gEUDwas normalized to a reference volume of 200 cm3. For each patient and each OAR, an average
of the treatment gEUDs (gEUDtreat) was calculated for CRT and IMRT. The paired t test was used to compare
IMRTwith CRT and gEUDtreat with gEUDplan.
Results: The mean gEUDtreat was reduced from 43 to 40 Gy, 47 to 46 Gy, and 48 to 45 Gy with IMRT for the bowel,
rectum, and bladder, respectively (p < 0.001). Differences between the gEUDplan and gEUDtreat were not signiﬁcant
(p > 0.05) for any OAR but was >6% for the bowel in 6 of 20 patients.
Conclusion: Intensity-modulated RTreduced the bowel, rectum, and bladder gEUDs also under inﬂuence of OAR
motion. Neither CRT nor IMRT was robust against bowel motion, but IMRT was not less robust than
CRT.  2008 Elsevier Inc.
Intensity-modulated radiotherapy, Prostate cancer, Lymph nodes, Bowel, Organ motion.
INTRODUCTION
The motivation for introducing intensity-modulated radio-
therapy (IMRT) for the treatment of pelvic lymph nodes in
prostate cancer patients has been to reduce the incidence of
gastrointestinal (GI) adverse effects and, if possible, to esca-
late the dose to the pelvic lymph nodes. Several planning
studies have demonstrated the superiority of IMRT compared
with conformal RT (CRT) to shape the dose distribution to
the planning target volume (PTV), thereby reducing the
dose to the main organs-at-risk (OARs) (i.e., the bowel,
rectum, and bladder) (1–13). Also, a few clinical studies
have indicated a better outcome with IMRT (4, 6, 13, 14).
Although IMRT provides the possibility for improving
treatment outcome, it is not straightforward to exploit this po-
tential fully. First, knowledge about the radiobiologic mech-
anisms behind GI adverse effects is limited and inﬂuenced by
the characteristic dose patterns of previous treatment ap-
proaches. Second, the mobility of the pelvic organs is consid-
erable, especially for the bowel, such that estimates of both
the applied dose and the dose prescription for optimization
are uncertain. Although a topic for planning and evaluation
of three-dimensional CRT, these issues become even more
pronounced with IMRT, because the dose distribution can
be shaped more freely. In contrast to IMRT, three-dimen-
sional CRT planning is target centric and does not need
a planning OAR volume concept (15). Thus, CRT and
IMRT dose distributions would show different characteristics
in the presence of organ movements.
The aim of the present studywas to understand these differ-
ences better. Because the examined IMRT approach applies
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the OAR contours from one computed tomography (CT) scan
as the basis for dose optimization, no attemptwasmade to cor-
rect for OARmotion during planning. We, therefore, hypoth-
esized that IMRT would be less robust against OAR
movement than would CRT. By robust, we mean that the
dosemetrics of the planwould be predictable towithin a toler-
able uncertainty of the metrics of the applied dose. In other
words, does ‘‘better’’ in planning stay ‘‘better’’ in application,
or is the planning advantage an illusion? Hence, a second aim
of this studywas to determinewhether the IMRTapproach ac-
tually is superior to CRT when also considering OAR move-
ment. As ameasure for evaluating theOARdoses,we used the
generalized equivalent uniform dose (gEUD). The gEUD has
not been frequently used for the bowel; therefore, we discuss
how this parameter can be calculated for this organ.
METHODS AND MATERIALS
The patient data (16), as well as the procedure for the deﬁnition of
targets and treatment planning and delivery (including patient
setup), has been previously described in detail (13). A brief descrip-
tion of the materials and planning procedures is outlined.
Patient data
A group of 20 male patients with muscle-invasive transitional cell
urinary bladder cancer was used. Of these 20 patients, 14 received
RT at Haukeland University Hospital (HUH) during 2000 and
2001, and 6 were treated at Edinburgh Cancer Centre (ECC) in
2003. For the whole group, patient age was 58–87 years. Repeat
CT scans were acquired once and twice weekly for the patients
treated at HUH and ECC, respectively.
Repeat CT scanning and deﬁnition of normal tissues
Overall, one planning CT scan and ﬁve to eight treatment CT
scans were acquired for each patient, giving a total of 149 scans,
all covering the pelvic region up to the sacral promontory or above.
All patients were scanned in the supine position with a 3- or 5-mm
slice thickness. The treatment scans were registered to the planning
scan using the bony anatomy.
In each of these scans, the bladder, rectum, and bowel were out-
lined. One of us (L.P.M.) did the outlining for the patients from
HUH, and a physician from ECC did the outlining for the patients
treated at ECC, except for the bowel in the planning scans, which
was outlined by another one of us (L.B.H.). The same instructions
for outlining were followed by all three operators. The bowel vol-
ume included all parts of the small and large bowel located below
the sacral promontory. For the rectum, we applied the ﬁrst slice be-
low the rectosigmoid ﬂexure as the superior/cranial limit and the ﬁrst
slice above the anal verge as the inferior/caudal limit. All three or-
gans were deﬁned with their contents. All contours for the patients
from ECC were reviewed by one of us (L.B.H.) to ensure the same
deﬁnitions for outlining had been used for patients from ECC and
HUH. The organ outlines in the treatment scans were transferred
to the planning scan and saved as separate Digital Imaging and
Communications in Medicine (DICOM) ﬁles. The planning outlines
were actively used during optimization, and the treatment outlines
were only used for evaluation.
Deﬁnition of target volumes
Using the Eclipse treatment planning system (Varian Oncology
Systems, Palo Alto, CA), one radiation oncologist (S.I.H.) with del-
egated responsibility for prostate cancer contoured the prostate, sem-
inal vesicles, and relevant lymph nodes on the planning CT scans.
The lymph node volume encompassed the internal and external iliac
vessels and a rim of about 2.5 cm along the pelvic wall between these
vessels. The presacral nodes were not included. These volumes were
then extendedwith margins to produce the PTV. Around the prostate
and seminal vesicles, we applied a margin of 15mm in all directions,
except for posteriorly, where a 10-mm margin was used. The lymph
node volume was included with an isotropic 10-mm margin.
Treatment planning
Following the planning procedures used at HUH, we created
a three-dimensional CRT plan and an IMRT plan for simulation
of the ﬁrst treatment phase (prescribed dose, 50 Gy). The CRT
plan consisted of two opposing anterior and posterior beams and
two opposing lateral beams (gantry angles, 0, 90, 180, and
270), with all beams having a 15-MV beam quality. All beams
were shaped with a MillenniumMLC-120 multileaf collimator (Var-
ian Medical Systems) conformed to the PTV with a margin of ap-
proximately 10 mm superiorly and inferiorly and 6 mm laterally,
except in the posterior direction, where the leaves were pulled closer
toward/into the PTV to shield the rectum (Fig. 1). The collimator an-
gle of the anterior and posterior beams was rotated to 90 and a few
multileaf collimator leaves were positioned between the lobes of the
Fig. 1. Frontal and lateral beam’s eye view of 1 patient showing the planning target volume (red), rectum (green), and the
position of multileaf collimator leaves from the conformal radiotherapy plan.
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PTV for 5 patients, in whom this was possible (Fig. 1). Although
aiming for a dose of 95–107% of the prescribed dose to the PTV,
a minimal point dose of 90% was accepted in the posterior part of
the PTV to avoid an unacceptably high rectum dose (Fig. 2).
For the IMRT plan, we used a seven-ﬁeld beam arrangement
(gantry angles, 0, 51, 103, 154, 206, 257, and 309) with
the same beam quality as for the CRT plan (i.e., 15 MV). The
minimal dose criterion of 95% of the prescribed dose to the PTV
was given the greatest priority during the optimization. For the
OARs, we used objectives at 30, 40, and 50 Gy. These were deﬁned
relative to the dose–volume histogram (DVH) obtained from the
CRT plan. For the bowel, rectum, and bladder, the DVH objectives
were set to 50%, 75%, and 75%, respectively, of the CRT DVH. In
addition, hot spots in the unspeciﬁed normal tissue were avoided by
applying a maximal dose objective (95% of the prescribed dose) to
the tissue surrounding the PTV with a distance of $3–5 mm from
the PTV. One radiation oncologist (S.I.H.) reviewed all treatment
plans.
Deﬁnitions and gEUD calculation
For all patients, both dose distributions were calculated on the
planning CT scan using a 2.5  2.5-mm2 grid size and exported
from Eclipse as DICOM ﬁles. For each patient, the structure ﬁles
from the CT scans were sorted chronologically with j = 0 for the
planning CT, and j e[1, N] for the treatment CT scans (with N being
the number of treatment CT scans). Dose matrices and organ out-
lines (regions of interest [ROIs]) were then imported into VerA
(an in-house created software program written in Interactive Data
Language) as DICOM RT and DICOM structure ﬁles. The CT co-
ordinates of the ROIs (given in the DICOM structure ﬁles) were ap-
proximated by the closest pixel coordinates of the dose matrix, and
the DVH for the ROI was calculated from all pixels within the ROI.
The Interactive Data Language was also used for calculating the
gEUD from each of the 894 OAR DVHs (using a resolution of 1
Gy). Because less than the whole bowel volume was contoured,
we extended the gEUD concept of Niemierko (17, 18) to calculate
the gEUD relative to an absolute reference volume (Vref):
gEUD ¼
 
1
Vref
X
i
viD
k
i
!1
k
(1)
where (vi,Di) denotes the ith bin of the differential DVH, and k is as-
sociated with the volume effect of the organ considered. A Vref of
200 cm3 was used for bowel, and the gEUD for the rectum and blad-
der was calculated relative to the whole organ volume. For the k pa-
rameter we used 4, 12, and 8 for the bowel, rectum, and bladder,
respectively (19, 20). A DVH reduction with k = 12 practically
only considers the volume elements receiving$80% of the maximal
OAR dose, while a reduction with k = 4 would also consider the vol-
umes receiving intermediate doses (>50%) but would weigh these
against greater dose volumes. For each patient and each organ, we
also calculated the average value of the gEUDs obtained from the
N treatment CT scans:
gEUDtreat ¼ 1
N
XN
j¼1
gEUDj (2)
as well as its standard deviation:
SDtreat ¼
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
gEUDj  gEUDtreat
2vuut (3)
In analogy to gEUDtreat, gEUDj=0 was denoted gEUDplan.
We also compared the OAR volumes receiving doses greater
than x 3 {25, 30, 35, 40, 45, 50}Gy. Vx will henceforth be referred
to as the volume (absolute or relative) receiving more than xGy,
Vxtreat as the average of Vx obtained from the treatment DVHs,
and Vxplan as Vx obtained from the planning DVH.
Fig. 2. Illustration of improved target coverage obtained with (Left) intensity-modulated radiotherapy compared with
(Right) conformal radiotherapy.
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Statistics for comparison
After conﬁrming the presence of normality by plotting histograms
and performing the one-sample Kolmogorov-Smirnov test on the
test variables (the paired differences), the paired t test was used
for comparison of the gEUDtreat, SDtreat, and Vxtreat values obtained
with CRT with the values obtained with IMRT. We also compared
gEUDplan with gEUDtreat (and Vxplan with Vxtreat) for both CRT and
IMRT. All statistical tests were performed using Statistical Package
for Social Sciences, version 13.0 (SPSS, Chicago, IL).
RESULTS
The mean values of the bowel, rectum, and bladder gEUD
treat and Vtreat across the group of patients are listed in Tables
1 and 2, respectively. Overall, reduced doses to the OARs
were obtained using IMRT compared with those using CRT.
Figure 3 shows the absolute bowel volumes receiving
doses >20–50 Gy. As expected, IMRT shifts the dose for
the parts of the bowel outside the PTV that would have re-
ceived 40–50 Gy using CRT toward 30 Gy. Consequently,
a greater volume (p < 0.001) of the bowel would receive
doses $30 Gy with IMRT compared with CRT (Fig. 3).
The CRT dose distribution consists mainly of two dose levels
(i.e., 25 and 45–50 Gy), resulting from the contribution from
two or four treatment ﬁelds, and hence only a small fraction
of the bowel would receive exactly 30 Gy with CRT. In the
case of IMRT, Vtreat was signiﬁcantly greater than Vplan
(p = 0.003–0.03) for all intermediate dose levels investigated
(i.e., 25–40 Gy); such a difference was found for V25, V45,
and V50 for CRT (p = 0.001–0.04).
For the bowel, an average reduction in gEUDtreat of 7% rel-
ative to CRT was obtained with IMRT (Fig. 4 and Table 1).
While 8 of 20 patients would have received a bowel gEUD of
>45 Gy with CRT, only 1 patient had a gEUDtreat >45 Gy
with IMRT (Fig. 4). However, 4 patients did not beneﬁt
from IMRT with respect to a reduced bowel gEUD (Fig. 4;
Patients 2, 6, 7, and 13). These were among the 5 patients
who had a conformal plan setup with a rotated collimator
(as shown in Fig. 1), producing a more conformed dose dis-
tribution compared with the standard CRT plan.
The differences between the patients were large, and the
bowel gEUDtreat ranged from 28 to 51 Gy with CRT and
25 to 48 Gy with IMRT (Fig. 4). Also the intrapatient varia-
tion (SDtreat) was considerable for this organ (Table 3). The
same pattern was seen for both techniques in the differences
between the planning and treatment bowel gEUDs (Fig. 4 and
Table 3). In 6 of the 20 patients, the difference between the
gEUDplan and gEUDtreat was >6% relative to the gEUDplan
(Fig. 4). A difference >20% was observed in 2 patients
Table 1. Mean and standard deviation of gEUDtreat for all
patients
gEUDtreat (Gy)
OAR CRT IMRT p
Bowel 42.6  6.7 39.5  4.9 <0.001
Rectum 47.0  1.1 46.2  1.1 <0.001
Bladder 48.1  1.3 45.1  1.6 <0.001
Abbreviations: gEUDtreat = average of treatment generalized
equivalent uniform doses; OAR = organ at risk; CRT = conformal
radiotherapy; IMRT = intensity-modulated radiotherapy.
Table 2. Mean Vtreat for all patients
Vtreat
CRT IMRT p
Bowel volume (cm3)
$25 Gy 258 (123–440) 237 (126–402) 0.003
$30 Gy 140 (52–250) 170 (82–302) <0.001
$35 Gy 119 (27–222) 113 (38–213) 0.097
$40 Gy 108 (19–207) 75 (16–159) <0.001
$45 Gy 98 (12–193) 44 (4–112) <0.001
$50 Gy 59 (1–143) 6 (0–15) <0.001
Rectum (%)
$25 Gy 97 (86–100) 94 (84–99) <0.001
$30 Gy 90 (77–99) 89 (74–97) 0.120
$35 Gy 82 (66–97) 79 (59–92) 0.116
$40 Gy 75 (57–92) 67 (39–84) 0.001
$45 Gy 64 (43–80) 51 (28–70) <0.001
$50 Gy 9 (0–40) 3 (0–8) 0.008
Bladder (%)
$25 Gy 99 (92–100) 98 (88–100) 0.051
$30 Gy 93 (75–100) 89 (71–100) 0.003
$35 Gy 87 (65–100) 76 (46–98) <0.001
$40 Gy 83 (60–99) 62 (34–90) <0.001
$45 Gy 78 (53–96) 46 (23–70) <0.001
$50 Gy 25 (6–72) 9 (3–20) <0.001
Abbreviations: Vtreat = average cutoff volume from treatment
dose-volume histogram; other abbreviations as in Table 1.
Data in parentheses are ranges.
Fig. 3. Mean and standard deviation of bowel volume receiving
more than xGy obtained from planning dose–volume histogram
(VxPlan) and average Vx obtained from treatment dose–volume his-
tograms (Vxtreat) for all patients for conformal radiotherapy (CRT)
and intensity-modulated radiotherapy (IMRT).
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(Patients 8 and 11); however, Patient 8 was obese and Patient
11 had an abnormal bladder shape (i.e., a bifurcation). Ex-
cluding these 2 patients, gEUDtreat was, on average, 1%
greater than the gEUDplan for both techniques. However,
the difference between the bowel gEUDplan and gEUDtreat
was not signiﬁcant for either IMRT (38.4 Gy vs. 39.5 Gy,
p = 0.08) or CRT (41.4 Gy vs. 42.6 Gy, p = 0.13).
For the rectum, an average reduction in gEUDtreat of 2%
relative to CRT was obtained with IMRT (Fig. 4 and Table
1). Of the 20 patients, 6 did not beneﬁt from IMRT with re-
spect to a reduced rectum gEUD (Fig. 4; Patients 2, 6, 11, 13,
17, and 19); that is, gEUDtreat/gEUDplan $1.00. Less inter-
and intrapatient variations were observed for the rectum
than for bowel (Fig. 4 and Table 3). For all patients except
2, the difference between gEUDplan and gEUDtreat was within
2% of the gEUDplan and, on average, gEUDtreat was equal to
gEUDplan for both techniques (Fig. 4 and Table 3).
For the bladder, gEUDtreat was again reduced using IMRT
6% on average (Fig. 4). All patients beneﬁted from IMRT
with respect to a reduced bladder gEUDtreat (Fig. 4). The het-
erogeneity of the IMRT dose distribution across the bladder
volume was reﬂected in a larger SDtreat with IMRT than with
CRT (Table 3). On average, gEUDtreat was also equal to
gEUDplan for the bladder (Fig. 4).
We accepted poorer geometric PTV coverage for CRT
than for IMRT, and this was reﬂected in the minimal point
doses to the PTV, which increased from 37–46 Gy using
CRT to 44–47 Gy using IMRT (p < 0.001).
Fig. 4. (Upper) Generalized equivalent uniform dose (gEUD) from planning dose-volume histogram (gEUDplan) (points)
and average of treatment gEUDs (gEUDtreat) (streaks), with ranges marked by vertical lines in the case of conformal ra-
diotherapy (CRT) (black) and intensity-modulated radiotherapy (IMRT) (gray) for each patient and for organs at risk con-
sidered. Horizontal dotted black and gray lines mark mean of gEUDtreat across group in case of CRT and IMRT,
respectively. (Lower), gEUD ratios between IMRT and CRT shown in black; dotted black line represents ratio between
planning gEUDs (IMRTplan/CRTplan), and solid black line indicates ratio between treatment gEUDs (IMRTtreat/CRTtreat).
Also, gEUDtreat/gEUDplan ratios shown. Dashed blue line indicates gEUDtreat/gEUDplan for CRT, and dash-dotted orange
line indicates gEUDtreat/gEUDplan for IMRT.
Table 3. Mean ratio between gEUDtreat and gEUDplan and mean of individual standard deviations (SDtreat) in gEUDtreat
gEUDtreat/gEUDplan SDtreat (Gy)
OAR CRT IMRT CRT IMRT p*
Bowel 1.03 (0.86–1.24) 1.04 (0.89–1.31) 2.2 (0.5–5.0) 2.1 (0.8–5.2) 0.09
Rectum 1.00 (0.98–1.02) 1.00 (0.98–1.03) 0.5 (0.2–1.1) 0.7 (0.1–2.1) 0.05
Bladder 1.00 (0.98–1.04) 1.00 (0.95–1.09) 0.4 (0.1–1.2) 0.8 (0.2–1.7) <0.001
Abbreviations: gEUD = generalized equivalent uniform dose; gEUDplan = gEUD from planning dose-volume histogram; SDtreat = standard
deviations from gEUDtreat; other abbreviations as in Table 1.
Data in parentheses are ranges.
* p Values from comparison of SDtreat between CRT and IMRT.
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DISCUSSION
Several planning studies of pelvic RT for prostate cancer
have emphasized the superiority of IMRT compared with
CRT (1–13). The large mobility of the relevant OARs for
this treatment approach could, however, jeopardize normal
tissue sparing. From the present study, we can conclude
that the examined IMRT approach still allows for reduced
doses to the OARs and better target coverage, also when tak-
ing internal organ motion into account.
Evaluating the doses delivered to the bowel is difﬁcult, be-
cause knowledge about the correlation between dose–volume
parameters and the risk of GI adverse effects, especially diar-
rhea, is unclear. Although many clinical studies have recog-
nized small bowel complications, only a few studies have
reported a correlation with bowel dose–volume data (20–
25). Furthermore, the ﬁndings from these studies have been
ambiguous. Although Roeske et al. (20) found the absolute
small bowel volume receiving the prescription dose of $45
Gy (i.e., V45) to be the solitary cutoff volume to predict for
acute diarrhea in gynecologic patients undergoing IMRT,
others have reported correlations for lower dose cutoff vol-
umes (e.g., V5–V30), particularly for V15 (21, 22, 25). How-
ever, that the latter studies were of chemoradiotherapy for
rectal cancer predominantly performed with three-ﬁeld
CRT to a prescription dose of 45 Gy explains in part why
V15 gave such a strong correlation. As noted by Tho et al.
(22) and Baglan et al. (21), the effect of low-dose RT is im-
possible to isolate in these studies, because these volumes
correlate highly to high-dose volumes owing to limited
DVH variability. In addition, various combination schemes
of RT with pelvic surgery and chemotherapy could alter
the bowel’s response to RT.
It is, therefore, uncertain whether the reduction we saw in
V45 from IMRT in the present study would result in a lower
incidence of diarrhea in this group of patients, because IMRT
redistributed the dose such that the reduction in V45 had to be
repaid by a greater V30. Nevertheless, Ashman et al. (4) ob-
served a similar redistribution with IMRT and yet their pa-
tients experienced an improved GI toxicity proﬁle after
IMRT compared with after CRT. Also, the initial clinical re-
sults from HUH have been promising (13, 26).
However, the volumes receiving intermediate doses might
have an effect and should therefore not be neglected but
somehow be weighted against the high-dose volumes. One
efﬁcient method of doing this is to reduce the DVH by the
formalism of the gEUD. However, this relies on a proper es-
timation of k. For the rectum, the volume effect is fairly well
known (19), but for bowel and bladder parameter sets are
sparse and provisional. For the small bowel, Roeske et al.
(20) found k = 3.2  1.1 to provide the best ﬁt between the
incidence of Grade 2 acute diarrhea and V45. They further
suggested a threshold of 195 cm3 for this volume (20). On
the basis of these results, we chose k = 4 and Vref = 200
cm3 for the bowel. For the bladder, k was derived from the
clinical experience of EUD-based optimization of IMRT at
the University Clinic in Tu¨bingen (Germany).
A lack of correlation between the dose–volume parameters
for the bowel and the incidence of diarrhea could partly be
explained by the snapshot provided by a single CT scan,
which cannot represent the real treatment situation, because
it pictures a mobile organ in an arbitrary shape and position
(16, 27, 28). Consequently, depending on the heterogeneity
of the dose distribution, the planned DVH will not provide
a good estimate of the true bowel DVH. Kvinnsland and Mu-
ren (28) quantiﬁed large uncertainties in bowel DVHs from
CRT for bladder cancer due to organ motion and recommen-
ded careful interpretation and use of dose–volume constraints
for this organ, especially for use in IMRT optimization.
Because of our planning procedure, we suspected IMRT
would be less robust against bowel motion than CRT. How-
ever, in terms of systematic (gEUDplan vs. gEUDtreat) and
random (SDtreat) bowel gEUD variation, the same trend
was seen for both techniques (Table 3 and Fig. 4), although
different dose cutoff volumes contributed to the change in
gEUD with IMRT compared with CRT (Fig. 3). IMRT con-
formed the dose better to the PTV, and the whole-body V45
was, therefore, considerably smaller with IMRT than with
CRT (i.e., 1.2 0.2 dm3 vs. 1.5 0.2 dm3, p < 0.001). Com-
bined with a shrinkage in bladder volume (from Vplan = 183
 127 cm3 to Vtreat = 150 95 cm3, p = 0.04), this led to a sig-
niﬁcantly larger bowel V45treat than V45plan in the case of
CRT (p = 0.04) but not in the case of IMRT (p = 0.06). Be-
cause of this, and because a change in V45 would alter the
gEUD more than a comparable change in lower dose cutoff
volumes, IMRT did not turn out to be less robust than
CRT. The present study was performed on patients who
had been instructed to have an empty bladder during treat-
ment, although these patients are normally instructed not to
void during the last hour before treatment.
To circumvent the uncertainties connected to the planning
bowel DVH, some investigators (3, 7, 11, 29) outline all the
space that could possibly be occupied by bowel and apply ob-
jectives/constraints to this volume. Alternatively, one could
use margins around the bowel (16). However, because these
approaches are nonspeciﬁc (16), they would unduly restrict
the degrees of freedom. This would have to be repaid through
either relaxation of the OAR constraints or by allowing
a more inhomogeneous PTV dose distribution to remain
within the space of physically obtainable solutions to the op-
timization problem. Nevertheless, these methods are believed
to produce dose distributions that are more robust against
bowel motion. However, they might not necessarily be
more robust for the target, which was not observed in the
present study. Another option would be to include informa-
tion about bowel motion into the optimization by using cov-
erage probabilities or similar approaches (30).
For the rectum, we found no change in the gEUD from
planning to treatment. However, this result should not be
transferred to treatments in which the presacral and/or peri-
rectal lymphatics are included in the target volume, because
a dose distribution with high doses surrounding the rectum
(see Fig. 4 in the report by Price et al. [12]) would probably
be less robust against rectal motion.
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The limited reduction in rectal gEUD with IMRT in the
present study was partially a result of the better PTV cover-
age with IMRT compared with CRT, but also because of
the large margins around the prostate and seminal vesicles
(10–15 mm).
In the present study, we used OAR contours from the treat-
ment CT scans and the dose matrix calculated from the plan-
ning CT scan to obtain the treatment DVHs and gEUDs (i.e.,
the dose was not recomputed on the repeat CT scans). This
assumption of dose invariance is not entirely valid, because
the shape of the patient, as well as the presence of air cavities
within the pelvis, changes during the treatment period. Fur-
thermore, setup uncertainties were not considered but were
accounted for through the CTV to PTV margin. Depending
on the method chosen for setting up the patient, the true de-
livered gEUD for the OARs would differ from the gEUDtreat.
However, as long as the systematic setup errors of the bony
anatomy are minimized, these uncertainties are believed to
be minor sources of errors compared with the internal organ
movements considered.
gEUDtreat is a surrogate for the real accumulated gEUD,
because it is calculated as the average value of a limited
number of treatment gEUDs (whose distribution is not nec-
essarily gaussian) and under the above-mentioned assump-
tions. Estimating the accumulated gEUD would require
deformable registration algorithms. Such algorithms are cur-
rently available for the rectum and bladder (31, 32), but not
for the bowel. Because of the chaotic pattern of the large
amplitude movements of the bowel, and the complete ab-
sence of landmarks, tracking bowel doses would be im-
mensely difﬁcult and probably not feasible. Still, it might
be possible to ﬁnd surrogates that provide a better estimate
for the real accumulated bowel gEUD than gEUDtreat.
CONCLUSION
Intensity-modulated RT was better than CRT for the
planned dose. Internal organ motion made all metrics
(gEUDs and volume parameters) worse, sometimes signiﬁ-
cantly so. However, IMRT remained better than CRT, also
under the inﬂuence of internal organ motion. The gEUD
was less sensitive toward bowel motion than were the volume
parameters. For the bowel, gEUD should preferably be calcu-
lated relative to an absolute reference volume. The examined
IMRT planning approach (of one contour only) is reasonably
robust and therefore considered clinically acceptable.
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